James A. Goldstein, MD, FSCAI

Director, Research and Education
Beaumont Health System
Royal Oak, Michigan, United States

Dr. Goldstein is the director of research and education In the Department of cardiovascular medicine at William Beaumont Hospital. He has over 30 years of experience in the field of interventional cardiology. His main research interests are acute coronary syndromes and atherosclerotic plaque characterization and utilization of both direct coronary imaging (NIRS-IVUS )as well as noninvasive CT angiography to delineate coronary plaque morphology, composition and stability. He has also spent over 40 years researching acute right ventricular infarction in general and the benefits of reperfusion and mechanical support devices in RV shock.

Presentation(s):

• PATHOPHYSIOLOGY OF CARDIOGENIC SHOCK LV AND RV

  Saturday, February 25, 2023
  8:00 AM – 9:20 AM ET

  Disclosure information not submitted.

• Pathophysiology and Management of RV Shock

  Saturday, February 25, 2023
  8:16 AM – 8:24 AM ET

  Disclosure(s): ECLS, Inc which licenses radiation shiled technology to Image Diagnostics, Inc: Intellectual Property/Patents (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Officer or Board Member (Ongoing), Royalties (Ongoing)

• Panel Discussion: What Have We Learned From the Past 30 Years on the Pathophysiology of Cardiogenic Shock

  Saturday, February 25, 2023
  9:04 AM – 9:20 AM ET

  Disclosure information not submitted.

• Detection of Vulnerable Plaques by CT Angiography

  Saturday, February 25, 2023
  3:19 PM – 3:27 PM ET

  Disclosure(s): ECLS, Inc which licenses radiation shiled technology to Image Diagnostics, Inc: Intellectual Property/Patents (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Officer or Board Member (Ongoing), Royalties (Ongoing)

• Panel Discussion | Advances of Imaging to Detect Vulnerable Plaque: Can we Trust What we See?

  Saturday, February 25, 2023
  3:51 PM – 4:06 PM ET

  Disclosure(s): ECLS, Inc which licenses radiation shiled technology to Image Diagnostics, Inc: Intellectual Property/Patents (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Officer or Board Member (Ongoing), Royalties (Ongoing)

• Panel Discussion: Atherosclerosis Therapeutic Options and Management

  Saturday, February 25, 2023
  5:26 PM – 5:35 PM ET

  Disclosure(s): ECLS, Inc which licenses radiation shiled technology to Image Diagnostics, Inc: Intellectual Property/Patents (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Officer or Board Member (Ongoing), Royalties (Ongoing)

• Novel Technologies to Minimize Radiation Exposure to the Cath Lab Team

  Sunday, February 26, 2023
  9:37 AM – 9:45 AM ET

  Disclosure(s): ECLS, Inc which licenses radiation shiled technology to Image Diagnostics, Inc: Intellectual Property/Patents (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Officer or Board Member (Ongoing), Royalties (Ongoing)

• Panel Discussion: Keeping the Cath Lab Function Robust Post COIVD-19

  Sunday, February 26, 2023
  9:53 AM – 10:15 AM ET

  Disclosure(s): ECLS, Inc which licenses radiation shiled technology to Image Diagnostics, Inc: Intellectual Property/Patents (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Officer or Board Member (Ongoing), Royalties (Ongoing)